SAL
PTCT icon

SACKS & ASSOCIATES, LLC’s PTC Therapeutics PTCT Stock Holding History

SACKS & ASSOCIATES, LLC’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$263K Hold
3,869
– – 0.18% 74
2026
Q1 		$264K Hold
3,869
– – 0.2% 70
2025
Q4 		$294K Buy
+3,869
New +$281K 0.22% 67

Other funds holding PTCT

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

SACKS & ASSOCIATES, LLC's PTCT Position: Q2 2026 in Review

SACKS & ASSOCIATES, LLC held its PTC Therapeutics (PTCT) position steady in Q2 2026 at 3,869 shares worth $263K. The position accounts for 0.18% of the portfolio, ranked #74.

SACKS & ASSOCIATES, LLC first reported a position in PTCT in Q4 2025 and has held it in 3 quarters since. The position peaked at $294K in Q4 2025. 137 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • SACKS & ASSOCIATES, LLC held 3,869 shares of PTC Therapeutics worth $263K as of Q2 2026.
  • SACKS & ASSOCIATES, LLC left its PTC Therapeutics share count unchanged in Q2 2026.
  • PTC Therapeutics made up 0.18% of SACKS & ASSOCIATES, LLC's portfolio in Q2 2026, its #74 holding.
  • SACKS & ASSOCIATES, LLC first reported a position in PTC Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • SACKS & ASSOCIATES, LLC's PTC Therapeutics position peaked at $294K in Q4 2025.
  • 137 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on SACKS & ASSOCIATES, LLC's 13F filing for Q2 2026, filed 5 Aug 2026.